Table 2. Comparison of KIR and KIR ligand genotype frequencies between patients recurring vs. those who did not.
| KIR | Recurrent cases (n = 29) | Non-recurrent cases (n = 58) | P Value |
|---|---|---|---|
| 2DL1 | 29 (100%) | 48 (82.7%) | 0.017 |
| 2DL2 | 18 (62%) | 50 (86.2%) | 0.01 |
| 2DL3 | 16 (55.2%) | 23 (39.7%) | 0.17 |
| 2DL5A/B | 18 (62%) | 35 (60.3%) | 0.877 |
| 2DS1 | 14 (48.3%) | 26 (44.8%) | 0.761 |
| 2DS2 | 12 (41.4%) | 42 (72.4%) | 0.005 |
| 2DS3 | 7 (24.1%) | 27 (46.5%) | 0.043 |
| 3DS1 | 14 (48.3%) | 21 (36.2%) | 0.279 |
| Group C1 | 27 (93.1%) | 53 (91.4%) | 0.571 |
| Group C2 | 28 (96.6%) | 52 (89.7%) | 0.252 |
| A-Bw4 | 24 (82.6%) | 34 (58.6%) | 0.024 |
| 2DL1-group C2 | 28 (96.6%) | 43 (74.1%) | 0,011 |
| 2DL2-group C1 | 17 (58.6%) | 47 (81%) | 0,025 |
| 2DL3-group C1 | 15 (51.7%) | 19 (32.8%) | 0,087 |
| 2DS1-group C2 | 13 (44.8%) | 24 (41.4%) | 0,759 |
| 2DS2-group C1 | 12 (41.4%) | 40 (69%) | 0,013 |
| 3DS1-Bw4 | 13 (44.8%) | 19 (32.8%) | 0,193 |
| C2/ inhib KIR (+)* | 15 (51.7%) | 23 (39.7%) | 0.087 |
| C1/ inhib KIR (+)* | 15 (51.7%) | 13 (22.4%) | 0.021 |
*: Combination of Group C and any cognate inhibitory KIR